Skip to main content
ARAY logo

Accuray Incorporated (ARAY) Stock Price & Analysis

Accuray Incorporated (ARAY) — MoonshotScore 25/100 (Weak band), calculated Nov 22, 2026. Price $2.08 (-2.12%), as of the Nov 20, 2026 trading session; market cap $6.22M.

Educational signal · not a buy or sell recommendation · How to read this

$2.08 −$0.045 (-2.12%) Market Cap $6.22M

Accuray Incorporated · ARAY · NASDAQ

Accuray Incorporated develops and sells radiosurgery and radiation therapy systems for tumor treatment. Their CyberKnife and TomoTherapy systems offer precise radiation delivery, targeting tumors throughout the body.

Price as of Nov 20, 2026

Key Statistics

25 of 100

MoonshotScore v2 · Accuray (ARAY)

Weak
Business Quality Average (57)
Financial Safety Fragile (9)
Valuation Fair (63)
Growth Durability Shrinking (5)
Momentum Falling (15)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet and stalling growth, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Shrinking; Momentum: Falling.

  • EPS beat 4 of the last 8 reports
  • Altman Z -0.51 · Piotroski F 3
  • ROE -30.2% · ROA -0.4% · current ratio 1.56

Holding back: balance-sheet strain, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ARAY (58 recorded, newest six shown)
RecordedScoreBand
24Weak
29Weak
29Weak
25Weak
25Weak
25Weak

The score was 25 in the stored Nov 21, 2026 snapshot and remains 25 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$2.08
Change on the day-2.12%
52-week range$2.08 – $45.20
Market capitalisation$6.22M—
Shares traded on the day111.5K

Price & events

Other perspectives

Council score for Accuray (ARAY): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Negative
Valuation Moderate
Growth Durability Negative
Momentum Negative

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Negative
ROE Negative
Gross Margin Neutral

Read on: Nov 21, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Accuray (ARAY), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Accuray Incorporated (ARAY) is listed on NASDAQ. It employs 809 people and is led by Stephen R. LaNeve. The market values it at $6.22M.

2 · Latest results

What do the latest results show for Accuray (ARAY)?

Short answer · as of

Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$94M-$22M-$7.29 (diluted)
Q2 FY2026$102M-$14M-$4.55 (diluted)
Q3 FY2026$105M-$12M-$3.80 (diluted)
Q4 FY2026$101M-$2M-$0.61 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Accuray (ARAY)?

Short answer · as of

What is holding it back is balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -0.51 · Piotroski F 3. Trailing ratios: ROE -30.2% · ROA -0.4% · current ratio 1.56.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -0.51 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-30.2%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Accuray (ARAY)?

Short answer · as of

Current published price targets run low $2.00 · high $2.00 · consensus $2.00 · median $2.00 against a quoted price of $2.08 (as of Nov 20, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Accuray compare with its peers?

Short answer

Accuray's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Electromed, Inc. (ELMD) Same industry, near in market value$22.98 Nov 20, 2026$188M88 5-pillar Nov 22, 2026
Viemed Healthcare, Inc. (VMD) Same industry, near in market value$8.52 Nov 20, 2026$323M88 5-pillar Nov 22, 2026
Anika Therapeutics, Inc. (ANIK) Same industry, near in market value$13.23 Nov 20, 2026$177M72 5-pillar Nov 22, 2026
LENSAR, Inc. (LNSR) Same industry, near in market value$4.46 Nov 20, 2026$54.8M43 5-pillar Nov 22, 2026
Solana Company (HSDT) Same industry, near in market value$1.49 Nov 20, 2026$93.7M43 5-pillar Nov 22, 2026
Owlet, Inc. (OWLT) Same industry, near in market value$2.93 Nov 20, 2026$87.6M41 5-pillar Nov 22, 2026
Hyperion DeFi, Inc. (HYPD) Same industry, near in market value$2.08 Nov 20, 2026$31.5M38 5-pillar Nov 22, 2026
Inogen, Inc. (INGN) Same industry, near in market value$5.30 Nov 20, 2026$138M37 5-pillar Nov 22, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.07 Nov 20, 2026$247M36 5-pillar Nov 22, 2026
Apyx Medical Corporation (APYX) Same industry, near in market value$2.40 Nov 20, 2026$101M33 5-pillar Nov 22, 2026
SS Innovations International, Inc. (SSII) Same industry, near in market value$1.27 Nov 20, 2026$255M33 5-pillar Nov 22, 2026
Autonomix Medical, Inc. Common Stock (AMIX) Same industry, near in market value$0.89 Nov 20, 2026—32 5-pillar Nov 22, 2026
Accuray (ARAY) — this page$2.08$6.22M25

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$2.00 – $2.00
Consensus target
$2.00
Median target
$2.00

Consensus record · Captured .

Measured against a quoted price of $2.08 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 31, 2026

Transactions
13
Identified insiders
6
Purchases
0
Sales
0
Other transactions
13

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ARAY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ARAY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Accuray (ARAY)?

Read these with our analysis →

Accuray Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the ARAY research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ARAY?

ARAY carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Accuray Incorporated develops and sells radiosurgery and radiation therapy systems for tumor treatment.

Is ARAY a good stock to buy?

Stock Expert AI does not rate ARAY buy, sell or hold. Accuray Incorporated carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ARAY stock price today?

The last price recorded for Accuray Incorporated (ARAY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ARAY price target?

The analyst consensus price target for Accuray Incorporated (ARAY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for ARAY?

Accuray Incorporated faces several risks inherent to the medical device industry. Intense competition from larger, more established players like Varian Medical Systems and Elekta poses a significant threat. Product liability claims and recalls are also potential risks.

What are the key factors to evaluate for ARAY?

Accuray Incorporated (ARAY) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. By providing comprehensive training and support to clinicians, Accuray can ensure that its systems are used to their full potential. Not financial advice.

How frequently does ARAY data refresh on this page?

ARAY's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ARAY's recent stock price performance?

Accuray Incorporated (ARAY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative CyberKnife and TomoTherapy systems. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ARAY overvalued or undervalued right now?

Accuray Incorporated (ARAY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.